-
公开(公告)号：EP2201109B1
公开(公告)日：2012-10-03
申请号：EP08802426.0
申请日：2008-09-19
CPC分类号： A61K39/0002 , A61K38/00 , C12N9/6478 , C12Q1/68 , G01N33/573 , Y02A50/471 , Y02A50/473
摘要： The present invention relates to a truncated form of the secretory aspartyl proteinase 2 (Sap2), as well as to nucleic acid molecules encoding same. This truncated Sap2 polypeptide (tSap2) is surprisingly stable and devoid of enzymatic activity but retains full immunogenicity upon intravaginal administration and confers full protection against intravaginal challenge by the Candida fungus. The present invention further relates to compositions comprising tSap2 and to the use of tSap2 in the preparation of such compositions.
摘要翻译： 本发明涉及分泌型天冬氨酰蛋白酶2（Sap2）的截短形式，以及编码其的核酸分子。 这种截短的Sap2多肽（tSap2）令人吃惊地稳定，没有酶活性，但在阴道内给药时保留完全的免疫原性，并赋予假丝酵母属真菌侵袭阴道内攻击的完全保护作用。 本发明还涉及包含tSap2的组合物和tSap2在制备这些组合物中的用途。
-
公开(公告)号：EP2201109A1
公开(公告)日：2010-06-30
申请号：EP08802426.0
申请日：2008-09-19
CPC分类号： A61K39/0002 , A61K38/00 , C12N9/6478 , C12Q1/68 , G01N33/573 , Y02A50/471 , Y02A50/473
摘要： The present invention relates to a truncated form of the secretory aspartyl proteinase 2 (Sap2), as well as to nucleic acid molecules encoding same. This truncated Sap2 polypeptide (tSap2) is surprisingly stable and devoid of enzymatic activity but retains full immunogenicity upon intravaginal administration and confers full protection against intravaginal challenge by the Candida fungus. The present invention further relates to compositions comprising tSap2 and to the use of tSap2 in the preparation of such compositions.
-
公开(公告)号：EP1991564B1
公开(公告)日：2013-09-11
申请号：EP07733909.1
申请日：2007-03-02
申请人： Mymetics Corporation , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , Pevion Biotech Ltd.
CPC分类号： A61K9/1272 , A61K9/0019 , A61K9/0043 , A61K9/127 , A61K9/1271 , A61K39/12 , A61K39/21 , A61K2039/54 , A61K2039/545 , A61K2039/55555 , A61K2039/6018 , A61K2039/6075 , C07K14/005 , C12N2740/16122 , C12N2740/16134
-
4.发明公开
公开(公告)号：EP1680446A2
公开(公告)日：2006-07-19
申请号：EP04818758.7
申请日：2004-11-05
申请人： Pevion Biotech Ltd.
发明人： ZURBRIGGEN, Rinaldo
IPC分类号： C07K14/435 , A61K39/39 , A61K35/64
CPC分类号： C07K14/43572 , A61K39/39 , A61K2039/55516
摘要： The present invention provides novel adjuvant systems for the potentiation of immune responses against antigenic targets.
-
5.发明授权METHODS FOR SYNTHESIZING CONFORMATIONALLY CONSTRAINED PEPTIDES, PEPTIDOMETICS AND THE USE THEREOF AS SYNTHETIC VACCINES 有权合成方法阻碍构象肽PEPTIDOMETIKA及其作为合成疫苗
公开(公告)号：EP1629002B1
公开(公告)日：2009-01-07
申请号：EP04739532.2
申请日：2004-06-02
IPC分类号： C07K7/56 , C07K1/04 , C07K16/20 , A61K38/12 , A61K39/015
CPC分类号： G01N33/56911 , A61K38/00 , A61K39/00 , A61K39/015 , C07K7/56 , C07K16/205 , Y02A50/412 , Y02A50/58
摘要： The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain of an amino acid residue or analog and a (2S,4S)-4-functionalized proline residue. The invention further relates to the use of (2S,4S)-4-functionalized proline residues as building units in the synthesis of such peptidomimetics and to the use thereof as antigens, alone or in combination with suitable immunopotentiating delivery systems, for example immunopotentiating reconstituted influenza virosomes to elicit an immune response in a mammal. Moreover, the invention also relates to pharmaceutical compositions containing the same.
-
6.发明公开HIGH-EFFICIENCY FUSOGENIC VESICLES, METHODS OF PRODUCING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 审中-公开融合为他们的药物高融合效率，生产方法和组合物含统一气泡
公开(公告)号：EP1562550A1
公开(公告)日：2005-08-17
申请号：EP03779993.9
申请日：2003-11-19
申请人： Pevion Biotech Ltd.
IPC分类号： A61K9/127
CPC分类号： A61K9/1272 , A61K9/1271 , Y10S977/799 , Y10S977/80 , Y10S977/801 , Y10S977/802 , Y10S977/803 , Y10S977/804 , Y10S977/805 , Y10S977/808
摘要： The present invention relates to novel fusogenic vesicles as highly efficient and versatile encapsulation systems for delivering a substance of choice, such as nucleic acids, proteins, peptides, antigens, pharmaceutical drugs and cosmetical agents to cells and tissues.
-
公开(公告)号：EP2117590B1
公开(公告)日：2011-06-22
申请号：EP07857167.6
申请日：2007-12-31
申请人： Pevion Biotech Ltd.
IPC分类号： A61K39/145
CPC分类号： A61K39/145 , A61K39/0225 , A61K39/12 , A61K2039/5258 , A61K2039/53 , A61K2039/585 , C12N2760/12034 , C12N2760/16134 , C12N2760/16142
摘要： The present invention relates to the use of a lipid vesicle for the preparation of a medicament. The invention further relates to a method of treating and/or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof.
-
公开(公告)号：EP1833465B1
公开(公告)日：2010-03-17
申请号：EP05824123.3
申请日：2005-12-21
申请人： Pevion Biotech Ltd.
CPC分类号： A61K47/28 , A61K9/1272 , A61K9/19 , A61K31/704 , A61K39/015 , A61K39/12 , A61K39/145 , A61K2039/5258 , A61K2039/55555 , A61K2039/70 , C12N2760/16134 , C12N2760/16142 , C12N2760/16234
-
公开(公告)号：EP1991564A2
公开(公告)日：2008-11-19
申请号：EP07733909.1
申请日：2007-03-02
申请人： Mymetics Corporation , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , Pevion Biotech LTD.
CPC分类号： A61K9/1272 , A61K9/0019 , A61K9/0043 , A61K9/127 , A61K9/1271 , A61K39/12 , A61K39/21 , A61K2039/54 , A61K2039/545 , A61K2039/55555 , A61K2039/6018 , A61K2039/6075 , C07K14/005 , C12N2740/16122 , C12N2740/16134
摘要： The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein of a human immunodeficiency virus (HIV).
-
公开(公告)号：EP1973566B1
公开(公告)日：2012-06-27
申请号：EP06841001.8
申请日：2006-12-15
申请人： Pevion Biotech Ltd.
IPC分类号： C12N7/04 , A61K9/127 , A61K39/39 , A61K39/145
CPC分类号： A61K39/39 , A61K39/12 , A61K39/145 , A61K2039/5258 , A61K2039/55555 , C12N7/00 , C12N2760/16123 , C12N2760/16134
摘要： The invention relates to novel adjuvant systems that generate efficient immune responses against antigens of choice. The novel adjuvant systems of the present invention are based on virosomes. Thus the invention is directed to pharmaceutical compositions comprising virosomes, at least one antigenic molecule, and a carrier vehicle, methods for preparing such compositions and uses thereof.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.015 秒)
